華森製藥(002907.SZ):第二批藥品集採 2個品種均中標
格隆匯1月17日丨華森製藥(002907.SZ)公佈,2020年1月17日,公司參加了國家組織藥品集中採購和使用聯合採購辦公室(“聯採辦”)組織的第二批國家組織藥品集中採購。
公司已通過國家藥品監督管理局仿製藥質量和療效一致性評價的仿製藥品鋁碳酸鎂咀嚼片(0.5 g)、聚乙二醇4000散(10g)參加了此次集中採購,2個品種均中標。
第二批國家組織藥品集中採購堅持“4+7”試點及擴圍的基本原則、主要政策和組織操作模式,並進一步完善相關規則,推進藥品集中帶量採購制度的常態化,不再選擇部分城市試點,一次招採即在全國同步實施。
經國家藥品監督管理局網站查詢結果顯示,目前在中國市場生產和銷售鋁碳酸鎂咀嚼片的廠家共有31家,聚乙二醇4000散有5家。此次招標鋁碳酸鎂咀嚼片(0.5g)僅2家企業中標,聚乙二醇4000散(10g)有4家企業中標。公司此次中標將有利於進一步提升兩個產品的市場覆蓋及擴大銷售,提升公司品牌影響力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.